Last $19.35 USD
Change Today -0.43 / -2.17%
Volume 42.5K
SRDX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

surmodics inc (SRDX) Snapshot

Open
$19.72
Previous Close
$19.78
Day High
$19.74
Day Low
$19.08
52 Week High
03/7/14 - $25.99
52 Week Low
07/28/14 - $18.91
Market Cap
263.1M
Average Volume 10 Days
44.6K
EPS TTM
$0.89
Shares Outstanding
13.6M
EX-Date
--
P/E TM
21.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for SURMODICS INC (SRDX)

surmodics inc (SRDX) Related Bloomberg News

View More Bloomberg News

surmodics inc (SRDX) Related Businessweek News

No Related Businessweek News Found

surmodics inc (SRDX) Details

SurModics, Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neurovascular, urology, and other markets. The In Vitro Diagnostics segment provides in vitro diagnostic component products and technologies comprising protein stabilization reagents, substrates, polymers and reagent chemicals, antigens, and surface coatings for diagnostic immunoassay and molecular tests, and biomedical research applications. SurModics, Inc. markets its technologies and products worldwide through direct sales force consisting of sales professionals. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

114 Employees
Last Reported Date: 12/11/13
Founded in 1979

surmodics inc (SRDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.0K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $162.6K
Senior Vice President and General Manager of ...
Total Annual Compensation: $280.0K
Senior Vice President of Legal & Human Resour...
Total Annual Compensation: $280.0K
Vice President of Corporate Development & Str...
Total Annual Compensation: $266.5K
Compensation as of Fiscal Year 2013.

surmodics inc (SRDX) Key Developments

SurModics, Inc. Presents at C.L. King's Best Ideas Conference 2014, Sep-09-2014 11:00 AM

SurModics, Inc. Presents at C.L. King's Best Ideas Conference 2014, Sep-09-2014 11:00 AM. Venue: Omni Berkshire Place Hotel, New York, New York, United States. Speakers: Andy LaFrence, vice president of finance and chief financial officer, Gary R. Maharaj, Chief Executive Officer, President and Director.

SurModics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Revised Earnings Guidance for the Year 2014

SurModics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported total revenue of $14,616,000 against $14,289,000 a year ago. Operating income from continuing operations was $5,333,000 against $4,238,000 a year ago. Income from continuing operations before income taxes was $5,403,000 against $4,300,000 a year ago. Income from continuing operations was $3,674,000 or $0.27 basic and diluted per share against $3,178,000 or $0.22 basic and diluted per share a year ago. Net income was $3,598,000 or $0.26 basic and diluted per share against $3,131,000 or $0.21 diluted per share a year ago. The increase in earnings per share was driven both by continued SG&A expense management and the shifting of drug coated balloon expenditures due to the timing of preparation work for a first in human trial. For the nine months, the company reported total revenue of $42,103,000 against $41,835,000 a year ago. Operating income from continuing operations was $13,142,000 against $13,244,000 a year ago. Income from continuing operations before income taxes was $14,170,000 against $14,762,000 a year ago. Income from continuing operations was $9,763,000 or $0.70 diluted per share against $10,846,000 or $0.73 diluted per share a year ago. Net income was $9,687,000 or $0.70 diluted per share against $11,481,000 or $0.77 diluted per share a year ago. Net cash provided by operating activities from continuing operations was $12,466,000 against $11,904,000 a year ago. Net purchases of property and equipment was $1,165,000 against $1,448,000 a year ago. Non-GAAP operating income was $14,056,000 against $12,674,000 a year ago. Non-GAAP income from continuing operations was $9,634,000 or $0.69 diluted per share against $8,908,000 or $0.60 diluted per share a year ago. The company revised earnings guidance for the year 2014. The company updated its previously stated earnings per share outlook for fiscal 2014. The company now estimates diluted GAAP earnings from continuing operations to be in the range of $0.90 to $0.97 per share, an increase from previous guidance of $0.85 to $0.97 per share. The company is reaffirming its full-year revenue guidance to be in the range of $56.0 million to $58.5 million. The company also indicated that fiscal 2014 cash flow from operating activities should be at least $19.0 million, and capital expenditures are expected to range from $2.2 million to $2.5 million. For the full fiscal 2014 year, the company continues to anticipate a 31% to 33% tax rate.

SurModics Mulls Acquisitions

SurModics, Inc. (NasdaqGS:SRDX) is looking for acquisitions. Chief Executive Officer and President, Gary Maharaj said, “Turning now to corporate development. Let me reiterate that our ongoing cadence of activities continue to mature. We are actively seeking out and engaging the best acquisition opportunities that fit both our strategy for core business growth and core expansion.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRDX:US $19.35 USD -0.43

SRDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.28 USD +0.02
Biolase Inc $2.33 USD +0.03
Cerus Corp $4.11 USD +0.06
Cutera Inc $10.23 USD +0.03
STAAR Surgical Co $11.59 USD -0.15
View Industry Companies
 

Industry Analysis

SRDX

Industry Average

Valuation SRDX Industry Range
Price/Earnings 20.1x
Price/Sales 4.7x
Price/Book 2.8x
Price/Cash Flow 19.7x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SURMODICS INC, please visit www.surmodics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.